雲南鍺業(002428.SZ):同意鑫耀公司接受哈勃投資以貨幣方式向其增資3000萬元
格隆匯 12 月 10日丨雲南鍺業(002428.SZ)公佈,2020年12月10日,公司第七屆董事會第九次會議審議通過《關於控股子公司增資擴股暨公司放棄優先認繳出資權的議案》,同意控股子公司雲南鑫耀半導體材料有限公司(“鑫耀公司”)接受哈勃科技投資有限公司(“哈勃投資”)以貨幣方式向其增資人民幣3000萬元,出資額摺合註冊資本3000萬元,公司放棄對此次新增註冊資本的優先認繳出資權。
此次增資完成後公司持有53.26%的鑫耀公司股權,仍為鑫耀公司控股股東,仍保持對鑫耀公司的實際控制權,不會改變公司合並報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.